TITLE

QRXPHARMA INITIATES PIVITAL PHASE 3 STUDY OF MOXDUOIR

PUB. DATE
January 2010
SOURCE
Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the launch of QRxPharma Limited's Phase 3 study of MoxDuoIR for the management of moderate to severe post-operative pain following bunionectomy surgery. The trial is aimed at examining the efficacy and safety profiles of MoxDuoIR, compared with component doses of morphine and oxycodone alone. John Holaday, managing director and chief executive officer of QRxPharma, said that the trial is part of the company's compliance with a regulatory requirement for New Drug Application (NDA) approval.
ACCESSION #
47191579

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics